Literature DB >> 32276730

FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.

Samir Shah1, Hiteshi Dhami-Shah2, Swati Kamble3, Akash Shukla4.   

Abstract

Entities:  

Year:  2020        PMID： 32276730     DOI： 10.1016/j.jhep.2019.12.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  5 in total

Review 1.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-10-26

2.  Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.

Authors:  Aya Sugiyama; Akemi Kurisu; Bunthen E; Serge Ouoba; Ko Ko; Anvarjon Rakhimov; Tomoyuki Akita; Takayuki Harakawa; Toru Sako; Makoto Koshiyama; Takashi Kumada; Junko Tanaka
Journal:  BMC Gastroenterol       Date:  2022-05-13       Impact factor: 2.847

Review 3.  Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.

Authors:  Yoshio Sumida; Toshihide Shima; Yasuhide Mitsumoto; Takafumi Katayama; Atsushi Umemura; Kanji Yamaguchi; Yoshito Itoh; Masashi Yoneda; Takeshi Okanoue
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

4.  Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.

Authors:  Winston Dunn; Xing Song; Devin Koestler; Kristine Grdinovac; Eyad Al-Hihi; John Chen; Ryan Taylor; Jessica Wilson; Steven A Weinman
Journal:  J Gastroenterol Hepatol       Date:  2022-06-15       Impact factor: 4.369

5.  Embedding assessment of liver fibrosis into routine diabetic review in primary care.

Authors:  Dina Mansour; Allison Grapes; Marc Herscovitz; Paul Cassidy; Jonathan Vernazza; Andrea Broad; Quentin M Anstee; Stuart McPherson
Journal:  JHEP Rep       Date:  2021-04-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.